# Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.

> **NCT04118868** · PHASE1 · UNKNOWN · sponsor: **Sorrento Therapeutics, Inc.** · enrollment: 10 (estimated)

## Conditions studied

- Mycosis Fungoides

## Interventions

- **COMBINATION_PRODUCT:** Pembrolizumab administered using the Sofusa® DoseConnect™

## Key facts

- **NCT ID:** NCT04118868
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-31
- **Primary completion:** 2024-01-29
- **Final completion:** 2024-03-27
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04118868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04118868, "Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT04118868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*